Document is current
Any future updates will be listed below
-
Authors
Leving, Marika T. https://orcid.org/0000-0002-2732-4406
Gerritsma, Yoran H. https://orcid.org/0000-0002-9002-4000
Jackson, David J.
Bischoff, Erik W. M. A. https://orcid.org/0000-0002-3323-8475
Meijer, Jiska M.
Wouters, Hans
Blok, Bertine Flokstra-de
Kocks, Janwillem W. H.
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 26 September 2023
Accepted: 26 March 2025
First Online: 15 April 2025
Competing interests
: J.K. reports grants, personal fees, and non-financial support from AstraZeneca; grants, personal fees, and non-financial support from Boehringer Ingelheim; grants and personal fees from Chiesi Pharmaceuticals; grants, personal fees, and non-financial support from GSK; grants from Mundi Pharma; grants and personal fees from TEVA; personal fees from COVIS Pharma outside the submitted work; and personal fees from MSD; J.K. holds 72.5% of shares in the General Practitioners Research Institute (GPRI). J.K. holds the AsthmaOptimiser intellectual property rights. M.L., Y.H.G., J.M., H.W., and B.F.d.B. were employed by GPRI at the time of the study. In the past 3 years (2020–2022), GPRI conducted investigator- and sponsor-initiated research funded by non-commercial organizations, academic institutes, and pharmaceutical companies (including AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, Novartis, and Teva). D.J.J. has received advisory board and speaker fees from AstraZeneca, Boehringer, Chiesi, GlaxoSmithKline, Ingelheim, Novartis, and Sanofi. E.W.M.A.B. received unrestricted grants and speaker fees from Boehringer Ingelheim, GSK, and Chiesi.
